Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors
Using Irvin Yalom’s 11 therapeutic factors as a framework, the authors argue that psychedelic-assisted group psychotherapy (PAGP) may enhance group connectedness, interpersonal learning and prosocial behaviour by providing opportunities to practise newly acquired interpersonal skills. They outline existing PAGP models and supporting neurobiological evidence while noting challenges—such as a need for more structured sessions and potential reductions in patient openness—that can be mitigated by specialised therapist training.
Authors
- Gregor Hasler
Published
Abstract
Background
Despite the growth of psychedelic research, psychedelic-assisted group psychotherapy (PAGP) has received little attention in comparison to individual psychedelic-assisted psychotherapy models.
Methods
In this article, we aim to discuss the therapeutic potential of PAGP, as well as outline existing models and the challenges of this approach. Using Irvin Yalom’s 11 therapeutic factors of group therapy as a basic framework, we analyse current literature from clinical studies and neurobiological research relative to the topic of PAGP.
Results
We argue that combining psychedelic substances and group psychotherapy may prove beneficial for increasing group connectedness and interpersonal learning, potentially enhancing prosocial behaviour with direct opportunities to practice newly acquired knowledge about previously maladaptive behavioural patterns. Challenges regarding this approach include a more rigid therapy structure and potential loss of openness from patients, which may be ameliorated by adequate therapeutic training.
Conclusion
We hope for this article to support clinical research on PAGP by presenting a therapeutic framework and outlining its mechanisms and challenges.
Research Summary of 'Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors'
Introduction
Social relationships are essential for mental and physical health, and maladaptive social dynamics are implicated in many psychiatric disorders. Individual psychedelic-assisted psychotherapy (IPAP) has been developed to treat various mental health problems, but it is limited to the patient–therapist dyad and relies on patients' verbal reports. Psychedelic-assisted group psychotherapy (PAGP) offers the additional possibility that patients, peers and therapists can simultaneously observe and experience interpersonal difficulties in a shared, supportive environment. The authors situate PAGP historically—noting extensive mid-20th century psycholytic work and a recent meta-analysis that identified dozens of PAGP cases involving around 700 patients between 1956 and 1995—and observe that contemporary empirical research on PAGP remains sparse despite renewed clinical interest. Ponomarenko and colleagues set out to examine how PAGP might interact with established curative mechanisms of group therapy by using Irvin Yalom’s 11 therapeutic factors as an organising framework. The paper aims to synthesise clinical reports, contemporary trial data and relevant neurobiological findings to articulate potential benefits, mechanisms and challenges of PAGP, and to propose priorities for future research and clinical implementation.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Topics
- Author
- APA Citation
Ponomarenko, P., Seragnoli, F., Calder, A., Oehen, P., & Hasler, G. (2023). Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors. Journal of Psychopharmacology, 37(7), 660-678. https://doi.org/10.1177/02698811231155117
References (82)
Papers cited by this study that are also in Blossom
Agin-Liebes, G. I., Ekman, E., Anderson, B. T. et al. · Journal of Humanistic Psychology (2021)
Agin-Liebes, G. I., Malone, T., Yalch, M. M. et al. · Journal of Psychopharmacology (2020)
Anderson, B. T., Danforth, A. L., Daroff, R. et al. · EClinicalMedicine (2020)
Beaussant, Y., Tulsky, J., Guérin, B. et al. · Journal of Palliative Medicine (2021)
Bedi, G., Hyman, D., De Wit, H. · Biological Psychiatry (2010)
Bershad, A. K., Mayo, L. M., Van Hedger, K. et al. · Neuropsychopharmacology (2019)
Bershad, A. K., Miller, M. A., Baggot, M. J. et al. · Journal of Psychopharmacology (2016)
Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H. et al. · Frontiers in Pharmacology (2018)
Breeksema, J. J., Kuin, B. W., Kamphuis, J. et al. · Journal of Psychopharmacology (2022)
Breeksema, J. J., Niemeijer, A. R., Krediet, E. et al. · CNS Drugs (2020)
Show all 82 referencesShow fewer
Buchborn, T., Schröder, H., Höllt, V. et al. · Journal of Psychopharmacology (2014)
Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Carhart-Harris, R. L., Leech, R., Williams, T. M. et al. · British Journal of Psychiatry (2018)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Curry, D. W., Berro, L. F., Belkoff, A. R. et al. · Neuropharmacology (2019)
Hibicke, M., Gobbi, G. · Journal of Neuroscience (2020)
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Dos Santos, R. G., Osório, F. L., Rocha, J. M. et al. · Journal of Clinical Psychopharmacology (2021)
Frye, C. G., Wardle, M. C., Norman, G. J. et al. · Pharmacology Biochemistry and Behavior (2014)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Gasser, P. · Current Topics in Behavioral Neurosciences (2022)
Kirchner, K. · Journal of Psychopharmacology (2014)
Greenway, K. T., Garel, N., Jerome, L. et al. · Expert Review of Clinical Pharmacology (2020)
Greif, A., Šurkala, M. · Medicine Health Care and Philosophy (2020)
Gukasyan, N., Nayak, S. · Preprints (2020)
Guss, J. · Psychoanalytic Dialogues (2022)
Halpern, J. H., Sherwood, A. R., Passie, T. et al. · Medical Science Monitor (2008)
Hartogsohn, I. · Frontiers in Human Neuroscience (2018)
Holze, F., Avedisian, I., Varghese, N. et al. · Frontiers in Pharmacology (2021)
Holze, F., Caluori, T. V., Vizeli, P. et al. · Psychopharmacology (2021)
Holze, F., Ley, L., Müller, F. et al. · Neuropsychopharmacology (2022)
Holze, F., Vizeli, P., Müller, F. et al. · Neuropsychopharmacology (2019)
´dric, C., Hysek, M., Schmid, Y. et al. · Social Cognitive and Affective Neuroscience (2013)
Jerome, L., Feduccia, A. A., Wang, J. B. et al. · Psychopharmacology (2020)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Millière, R. · Frontiers in Human Neuroscience (2017)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2010)
Montgomery, C., Roberts, C. A. · Experimental Neurology (2021)
Moreton, S. G., Szalla, L., Menzies, R. E. et al. · Psychopharmacology (2019)
Nardou, R., Lewis, E. M., Rothhaas, R. et al. · Nature (2019)
Nielson, E. M., Guss, J. · Journal of Psychedelic Studies (2018)
Kraehenmann, R., Nielson, E. M., May, D. G. et al. · Frontiers in Pharmacology (2018)
Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
Oehen, P., Gasser, P. · Frontiers in Psychiatry (2022)
Oehen, P., Traber, R., Widmer, V. et al. · Journal of Psychopharmacology (2012)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Passie, T., Brandt, S. D. · New Psychoactive Substances (2018)
Pedersen, W., Copes, H., Gashi, L. · Acta Sociologica (2021)
Phelps, J. · Journal of Humanistic Psychology (2017)
Pokorny, T., Preller, K. H., Kometer, M. et al. · International Journal of Neuropsychopharmacology (2017)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Preller, K. H., Pokorny, D., Hock, A. et al. · PNAS (2016)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Preller, K. H., Vollenweider, F. X. · Frontiers in Psychiatry (2019)
Regan, A., Margolis, S., De Wit, H. et al. · PLOS ONE (2021)
Reiff, C. M., Richman, E. E., Nemeroff, C. B. et al. · American Journal of Psychiatry (2020)
Richards, W. A. · Journal of Humanistic Psychology (2016)
Rocha, J. M., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2019)
Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Roseman, L., Ron, Y., Saca, A. et al. · Frontiers in Pharmacology (2021)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Schenberg, E. E. · Frontiers in Pharmacology (2018)
Schmid, Y., Gasser, P., Oehen, P. et al. · Journal of Psychopharmacology (2020)
Stauffer, C., Anderson, B. T., Ortigo, K. M. et al. · ACS Pharmacology and Translational Science (2020)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Teixeira, P. J., Johnson, M. W., Timmermann, C. et al. · Journal of Psychopharmacology (2021)
Thomas, G., Lucas, P., Rielle Capler, N. et al. · Current Drug Abuse Reviews (2013)
Trope, A., Anderson, B. T., Hooker, A. R. et al. · Journal of Psychoactive Drugs (2019)
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Vizeli, P., Liechti, M. E. · Journal of Psychopharmacology (2017)
Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)
Wardle, M. C., De Wit, H. · Psychopharmacology (2014)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Wolff, M., Evens, R., Mertens, L. J. et al. · Frontiers in Psychiatry (2020)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Cited By (2)
Papers in Blossom that reference this study
Haikazian, S., Chen-Li, D., Johnson, D. et al. · Psychiatry Research (2023)
Pereira, L. · European Neuropsychopharmacology (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.